tirzepatide cardiovascular outcomes In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. β£, β£, Read the full SURPASS-CVOT ποΈ Rounds Table β Infographics
Pay in 4 interest-free payments of $5.94 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 12 - Aug 17



























